L&K Biomed Ltd.

Equities

A156100

KR7156100000

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. 23:00:00 30/05/2024 BST 5-day change 1st Jan Change
9,980 KRW -2.16% Intraday chart for L&K Biomed Ltd. +7.43% -1.96%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
L&K Biomed Ltd. announced that it has received KRW 20 billion in funding from a group of investors CI
L&K Biomed Ltd. announced that it expects to receive KRW 20 billion in funding from a group of investors CI
RootLoc Co., Ltd. announced that it has received KRW 3.686515722 billion in funding from L&K Biomed Ltd. CI
RootLoc Co., Ltd. announced that it expects to receive KRW 3.686515722 billion in funding from L&K Biomed Ltd. CI
L&K Biomed to Raise 36.6 Billion Won via Shares Issuance; Shares Plunge 23% MT
L&K Biomed Ltd.(KOSDAQ:A156100) added to S&P Global BMI Index CI
L&K Biomed Ltd. announced that it has received KRW 20 billion in funding from NH Investment & Securities Co., Ltd., Asset Management Arm, BNK Securities Co., Ltd., Investment Arm, Core Trend Investment Ltd., Kiwoom Securities Co., Ltd., Investment Arm and other investors CI
L&K Biomed Ltd. announced that it expects to receive KRW 20 billion in funding from NH Investment & Securities Co., Ltd., Asset Management Arm, BNK Securities Co., Ltd., Investment Arm, Core Trend Investment Ltd., Kiwoom Securities Co., Ltd., Investment Arm and other investors CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
L&K Biomed Ltd.'s Equity Buyback announced on May 30, 2017, has expired with 361,567 shares, representing 3.88% for KRW 2,986.18 million. CI
L&K Biomed Ltd.'s Equity Buyback Plan Extended till November 30, 2020. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
L&K Biomed Ltd.'s Equity Buyback Plan Extended till November 30, 2019. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
L&K Biomed Ltd.'s Equity Buyback Plan Extended till May 31, 2019. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
Tranche Update on L&K Biomed Ltd.'s Equity Buyback Plan announced on May 30, 2017. CI
L&K Biomed Ltd.'s Equity Buyback Plan Extended till November 30, 2018. CI
L&K Biomed Ltd. announced that it expects to receive KRW 16.99996803 billion in funding from ValueSystem Investment Management Corp., Susung Asset Management Co., Ltd., W Asset Management Co., Ltd., Orion Capital Management CI
Chart L&K Biomed Ltd.
More charts
L&K BIOMED CO., LTD. is a Korea-based company mainly engaged in the research, development and manufacture of medical devices. The Company’s products consist of medical devices and medical equipment. Its medical devices include cervical spine products, such as cervical plate systems, cervical screw systems and cervical cage system, as well as thoracolumbar spine products and others. Its medical equipment includes three dimensional (3D) full-body scanners. It also engages in the bio-similar business, which develops cell engineering.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A156100 Stock
  4. News L&K Biomed Ltd.
  5. L&K Biomed to Raise 36.6 Billion Won via Shares Issuance; Shares Plunge 23%